{
    "clinical_study": {
        "@rank": "23422", 
        "arm_group": {
            "arm_group_label": "Afatinib", 
            "arm_group_type": "Experimental", 
            "description": "Patient will receive afatinib once daily"
        }, 
        "brief_summary": {
            "textblock": "Primary objective of the trial is to evaluate the safety of afatinib in patients with\n      locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR (Epidermal\n      growth factor receptor) mutation(s) and have never been treated with an EGFR-TKI (tyrosine\n      kinase inhibitor). Secondary objective is to assess the time to symptomatic progression (as\n      judged by investigator)."
        }, 
        "brief_title": "Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non-Small-Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC)\n\n          -  presence of Epidermal Growth Factor Receptor (EGFR) mutations in tumor biopsy\n\n          -  male or female patients age 18 years or older\n\n        Exclusion criteria:\n\n          -  prior treatment with an EGFR tyrosine kinase inhibitor (TKI)\n\n          -  hormonal anti-cancer treatment within 2 weeks prior to start of trial treatment\n             (continued use of anti-androgens and / or gonadorelin analogues for treatment of\n             prostate cancer permitted)\n\n          -  radiotherapy within 14 weeks prior to drug administration except as follows:\n\n               1. palliative radiation to organs other than chest may be allowed up to 2 weeks\n                  prior to drug administration, and\n\n               2. single dose palliative treatment for symptomatic metastasis outside above\n                  allowance to be discussed with sponsor prior to enrolling."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953913", 
            "org_study_id": "1200.66"
        }, 
        "intervention": {
            "arm_group_label": "Afatinib", 
            "description": "Patient will receive afatinib once daily", 
            "intervention_name": "Afatinib", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.66.86002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China"
                    }, 
                    "name": "1200.66.86007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "1200.66.86015 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China"
                    }, 
                    "name": "1200.66.86012 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "1200.66.85201 Queen Mary Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "1200.66.85202 Queen Mary Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shatin", 
                        "country": "Hong Kong"
                    }, 
                    "name": "1200.66.85203 Prince of Wales Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chennai", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cuttack", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jaipur", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Karamsad", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kolkata,West Bengal", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madurai, Tamil Nadu", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maharashtra", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thiruvananthapuram", 
                        "country": "India"
                    }, 
                    "name": "1200.66.91007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore"
                    }, 
                    "name": "1200.66.65001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.66.88606 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.66.88604 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.66.88603 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.66.88602 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taoyuan County", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.66.88605 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Hong Kong", 
                "India", 
                "Singapore", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: China Food and Drug Administration (CFDA)", 
                "Hong Kong: Department of Health", 
                "India: Central Drugs Standard Control Organization", 
                "Singapore: Health Sciences Authority", 
                "Taiwan: Department of Health"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with drug related adverse events according to CTCAE 3.0.", 
            "safety_issue": "No", 
            "time_frame": "up to 65 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953913"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Clinical progression-free survival (PFS) defined as time from start of treatment to the date of first documented clinically significant symptomatic progression according to investigator's assessment or death.", 
                "safety_issue": "No", 
                "time_frame": "up to 65 weeks"
            }, 
            {
                "measure": "Overall survival (OS), defined as the time from start of treatment to the date of death (regardless of the cause of death) (optional endpoint, analyzed if enough data will be available).", 
                "safety_issue": "No", 
                "time_frame": "up to 65 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}